ABSCINT’s 68Ga-HER2 tracer is currently in a PHASE IIb clinical study in Belgium. To maximize the potential of unlocking the full clinical use of the HER2 tracer, ABSCINT offers the possibility to academic institutes/hospitals/companies to access our GMP grade precursor for investigator-initiated trials.
Try our solution
Please complete the form below when interested.
What we offer
Gain access to GMP grade precursor
Technical support for the radiopharmacy
Documentation to support trial application